News | Cardiovascular Ultrasound | February 18, 2025

UltraSight Expands Access to Cardiac Monitoring with AI

In a new study, non-sonographers to use UltraSight Real-Time Guidance for patients that require echocardiogram.


Feb. 11, 2025  — UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound, recently announced support from Bristol Myers Squibb (BMS) for a study that aims to improve access to echocardiographic assessments for patients with obstructive hypertrophic cardiomyopathy (oHCM).

Cardiac ultrasound is routinely used as an essential tool in the diagnosis and management of oHCM.

“UltraSight was founded with the goal of giving clinicians the ability to scan patients, wherever patients may be,” said Davidi Vortman, CEO of UltraSight. “By applying the power of machine learning to imaging, our aim is to streamline patient cardiac workflows with UltraSight real-time guidance for better, more efficient, and effective care. We are thrilled to receive support from BMS on this study with the goal of evaluating how this technology could help patients in need of consistent and reliable cardiac follow-up.”

The study will be launched at Cleveland Clinic and will focus on oHCM patients with the aim to validate the quality and accuracy of the monitoring echocardiograms performed by non-sonographers using UltraSight’s Real-Time Guidance software.

UltraSight’s Real-Time Guidance software provides real-time assistance for healthcare providers, guiding them to acquire diagnostic-quality echocardiography images. This approach is designed to optimize and streamline cardiac monitoring and other clinical workflows, enabling non-sonographers to achieve consistent, diagnostic-quality ultrasound thus improving patient access, operational efficiency, and patient care. By putting cardiac ultrasound in the hands of any medical professional, UltraSight’s software can help expand access to care, bringing cardiac ultrasound to more hospitals and cardiology clinics across the country.

“At Bristol Myers Squibb, we are committed to forging the path to improve cardiac care through innovative science,” said Cecilia Marta, Vice President, US Medical Cardiovascular. “This support of UltraSight  exemplifies our commitment to transforming patients’ lives through science by supporting cutting edge research.

Recruitment for the trial will begin in 2025. Please check https://clinicaltrials.gov/ for updates.

For more information about UltraSight, visit  https://ultrasight.com/. For more information about Bristol Myers Squibb, visit https://www.bms.com/.


Additional Content

News | Cardiovascular Ultrasound

Oct. 12, 2026 — Siemens Healthineers announced it ultrasound business plans to concentrate its efforts on cardiovascular ...

Home October 12, 2026
Home
News | Cardiovascular Ultrasound

Aug. 28, 2026 — GE HealthCare has announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid ...

Home August 28, 2026
Home
News | Cardiovascular Ultrasound

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Home August 11, 2026
Home
News | Cardiovascular Ultrasound

April 29, 2026 — Agitated Solutions, Inc.(ASI) has received CE Mark approval in the European Union for its novel device ...

Home April 30, 2026
Home
Feature | Cardiovascular Ultrasound | Kyle Hardner

The demand for ultrasound has outpaced the supply of trained sonographers over the past 15 years, straining hospital ...

Home March 11, 2026
Home
Subscribe Now